Tech Company M&A Transactions
Neurovance Acquisition
On 3/3/2017, Neurovance was acquired by Otsuka Pharmaceutical. Otsuka Pharmaceutical said the transaction price was $250 million.
Transaction Overview
Company Name
Acquired By
Announced On
3/3/2017
Transaction Type
M&A
Amount
$250,000,000
M&A Terms
Under the terms of the agreement, Otsuka America, Inc. (OAI), a subsidiary of OPC, is to provide an estimated USD $100 million in upfront payments at closing, up to $150 million in additional payments contingent on achievement of development and approval milestones, and future additional payments contingent on achievement of sales milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
43 Thorndike Street S1-3
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
Chief Financial Officer
Gregg Beloff
Chief Medical Officer
Ross Reife
VP - Finance
Vincent Pappafotopoulos
VP - Operations
Catherine O'Brien
Browse more venture capital transactions:
Prev: 3/3/2017: MediSafe venture capital transaction
Next: 3/3/2017: Moving Analytics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs